Bioxcel therapeutics reports second quarter 2022 financial results and recent operational highlights

Commercially launched igalmi™ (dexmedetomidine) sublingual film for the acute treatment of agitation in bipolar i or ii disorder and schizophrenia in adult patients

BTAI Ratings Summary

BTAI Quant Ranking